Sector News

Tergus Pharma to become full-fledged CDMO with new manufacturing facility

June 12, 2019
Life sciences

A small company that is all about the development of dermatology drugs has snagged a new investor and will soon start on a manufacturing facility that will catapult it into the CDMO market.

Tergus Pharma says an investment from private equity investor Great Point Partners will allow it to build its first commercial manufacturing facility. The Durham, North Carolina-based company currently provides topical formulation development, in vitro permeating testing, clinical trial materials and other services.

“For years we have discussed building a commercial facility. The equity capital from GPP will enable us to do this,” Tergus CEO Vijendra Nalamothu said in a statement.

Construction of the 100,000 square foot operation is slated to begin next month and to be complete in 2020, the company said. Terms of the deal were not disclosed.

The investment comes as the dermatology market is undergoing big changes. Nestle last month announced it is in exclusive talks to sell its skin health unit for about $10.1 billion to a consortium led by private equity EQT Partners. That comes just five years after the Swiss company moved deeper into the skin products to diversify away from slower sales in food.

The investors will pick up prescription brands including acne topical treatment Epiduo, as well as aesthetic and consumer products. About 5,000 employees also are expected to move.

Novartis is in the process of selling its Sandoz U.S. dermatology business, a dermatology development center and about 300 generics to India’s Aurobindo Pharma. Bayer in 2018 offloaded its prescription dermatology portfolio to Dutch company LEO Pharma.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.